GLPwatch
Papers (9189)
Page 83 of 154, ranked by citation count.
- Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
- Appetite suppressant semaglutide is to be made available to treat obesity in England.
- Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
- Semaglutide Misuse in Atypical Anorexia Nervosa-A Case Report.
- Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
- Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.
- Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.
- A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity.
- Identification of Potential Therapeutic Targets and Pathways of Liraglutide Against Type 2 Diabetes Mellitus (T2DM) Based on Long Non-Coding RNA (lncRNA) Sequencing.
- Cardiovascular Effects of Liraglutide.
- Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists.
- Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
- Maladaptive Eating Behaviours, Generalised Anxiety Disorder and Depression Severity: A Comparative Study between Adult Women with Overweight, Obesity, and Normal Body Mass Index Range.
- Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
- Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
- Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
- Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
- Optimizing outcomes for GLP-1 agonists.
- Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer <sup>68</sup>Ga-NODAGA-exendin-4.
- Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
- [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
- Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats.
- The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions.
- Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).
- Sustained exenatide delivery via intracapsular microspheres for improved survival and function of microencapsulated porcine islets.
- Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line.
- Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.
- Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.
- Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
- An unusual case of a generalised cutaneous drug reaction to liraglutide.
- Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels.
- A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
- Folic acid-modified reverse micelle-lipid nanocapsules overcome intestinal barriers and improve the oral delivery of peptides.
- No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
- The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.
- Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
- The comparison of three different molecular imaging methods in localization and grading of insulinoma.
- Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
- Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
- Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!
- Induction of insulin-producing cells from human pancreatic progenitor cells.
- Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
- Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
- Estimating the lives that could be saved by expanded access to weight-loss drugs.
- Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial.
- Wegovy: FDA approves weight loss drug to cut cardiovascular risk.
- Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial.
- Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
- Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
- Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
- Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial.
- Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
- Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
- Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
- Pancreatic imaging using an antibody fragment targeting the zinc transporter type 8: a direct comparison with radio-iodinated Exendin-4.
- A Specific HPLC Method to Determine Residual HEPES in [<sup>68</sup>Ga]Ga-Radiopharmaceuticals: Development and Validation.
- Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide.